IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Background Oncolytic viruses (OVs) have shown promise in containing cancer progression in both animal models and clinical trials. How to further improve the efficacy of OVs are intensively explored. Arming OVs with immunoregulatory molecules has emerged as an important means to enhance their oncolyt...
Main Authors: | Tianyue Chen, Xiangqing Ding, Qibin Liao, Jianqing Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/1/e001647.full |
Similar Items
-
Arming vaccinia virus for pancreatic cancer oncolytic virotherapy
by: Hiley, Crispin
Published: (2011) -
A T-cell engager-armed oncolytic vaccinia virus to target the tumor stroma
by: Feng Yu, et al.
Published: (2017-01-01) -
An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy
by: Deng L, et al.
Published: (2020-04-01) -
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice
by: Hajime Kurosaki, et al.
Published: (2021-04-01) -
Oncolytic virotherapy and modulation of tumor microenvironment with vaccinia virus strains
by: Patil, Sandeep S.
Published: (2014)